A comparison between IDH1/2 missense substitutions across four active‐site mutations among NSCLC (from Genetron, n = 17,978), glioma (from Genetron, n = 6319), and AML (from OHSU, n = 672) data sets32 revealed that IDH1 mutations in glioma were predominantly R132H (97.1%), however, they were more dispersed in NSCLC and AML (Figure. 2A, B). The gene discussed is IDH1; the disease is central nervous system cancer.